HomeEpcoritamab ByspEpcoritamab Bysp + Cyp Substrates

Does Epcoritamab Bysp Interact with Cyp Substrates?

Epcoritamab Bysp and Cyp Substrates have a moderate drug interaction according to U.S. FDA drug labeling data. Epcoritamab-bysp causes cytokine release that may suppress CYP enzyme activity, resulting in increased exposure of CYP substrates. This is more likely after the first dose and up to 14 days after the first 48 mg dose, and during/after CRS. The mechanism involves cytokine-mediated suppression of cyp enzyme activity. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Moderate
Epcoritamab Bysp Class
Bispecific CD20-directed CD3 T Cell Engager
Management
Monitor for effects
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Epcoritamab Bysp and Cyp Substrates occurs because cytokine-mediated suppression of cyp enzyme activity. Clinically, this means epcoritamab-bysp causes cytokine release that may suppress cyp enzyme activity, resulting in increased exposure of cyp substrates. this is more likely after the first dose and up to 14 days after the first 48 mg dose, and during/after crs. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.

What To Tell Your Doctor or Pharmacist

If you are taking Epcoritamab Bysp and your doctor is considering prescribing Cyp Substrates (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Epcoritamab Bysp(Epkinly)+💊 Cyp Substrates

Severity & Interaction Details

🟡
moderate
Be aware — moderate interaction
Documented interaction with manageable risk. May require dose adjustment or monitoring.
Severity scale
MinorContra
On record
Yes
Drug A class
Bispecific CD20-directed CD3 T Cell Engager
Drug B class
Source
NLP:epcoritamab-bysp

What this means in plain English

Epcoritamab-bysp causes cytokine release that may suppress CYP enzyme activity, resulting in increased exposure of CYP substrates. This is more likely after the first dose and up to 14 days after the first 48 mg dose, and during/after CRS.

What the FDA label says

"Cytokine-mediated suppression of CYP enzyme activity"

📖 Source: NLP:epcoritamab-bysp

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Epcoritamab Bysp and Cyp Substrates against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.